longbridgelongbridge
  • Products
  • Fees
  • Download
  • Promotions
    Welcome RewardsReferral ProgramUS Pre-Market Options Trading
  • For Institutions
    Corporate ServicesDevelopers
  • Help
  • About
    About LongbridgeLicense & RegulatoryMedia CoverageJoin Us
longbridge
  • Home
  • Discover
    Discover
    Global MarketsStock ScreenerFinancial Calendar
  • News & Info
    News & Info
    NewsInsightsLiveAcademy
  • Trade
  • PortAI
Home
Discover
News & Info
Trade
PortAI
Overview
Details
Chat
Novavax, Inc. (NVAX.US) Q1 2022 Earnings Conference Call
Live streaming time: 10/05/2022 01:09
Novavax is a clinical biotechnology company specialized in discovery, development, and commercialization of vaccines for infectious diseases prevention. The company makes use of its proprietary recombinant nanoparticle vaccine technology to produce candidate vaccines to counter known and emerging disease threats. Its vaccine candidates include ResVax and NanoFlu. The company also develops immunostimulatory saponin-based adjuvants via its wholly-owned Swedish subsidiary NovavaxAB. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Live Assistant
Risk and Disclaimer Statement:
The content on this page reflects the personal opinion of the author and is intended solely as general information for your reference. It shall not be construed as advice or a basis for any specific investment, business, or commercial decisions. The views expressed in the content do not represent any position of Longbridge or any investment recommendations or endorsements related to LongPort. Longbridge does not make any guarantee or commitment to the truthfulness, accuracy, or originality of the content. Investors should analyze the risks related to the investment based on their own circumstances and seek advice from a professional investment advisor when necessary.
© 2026 Longbridge|Disclaimer